Viridian Therapeutics, Inc.\DE short interest in 2026
In 2026, Viridian Therapeutics, Inc.\DE's disclosed short interest ran from 8.54% of shares outstanding on 15 Jan 2026 to 17.18% on 15 Sep 2026, a change of +8.64 percentage points. The year's high was 18.66% on 31 Jul 2026 and its low 8.13% on 13 Feb 2026, averaging 13.18% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.55 days on 31 Aug 2026. Full history: Viridian Therapeutics, Inc.\DE.
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 8.54% (15 Jan 2026)
- End of year
- 17.18% (15 Sep 2026)
- Change
- +8.64 pp
- High
- 18.66% (31 Jul 2026)
- Low
- 8.13% (13 Feb 2026)
- Average
- 13.18%
- Highest days to cover
- 16.55 (31 Aug 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 8.54% | 5.20 | |
| 30 Jan 2026 | 8.32% | 5.38 | |
| 13 Feb 2026 | 8.13% | 5.55 | |
| 27 Feb 2026 | 8.19% | 5.96 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 8.63% | 7.27 | |
| 31 Mar 2026 | 11.36% | 3.96 | |
| 15 Apr 2026 | 11.16% | 2.59 | |
| 30 Apr 2026 | 12.06% | 6.90 | |
| 15 May 2026 | 13.84% | 3.06 | 10-Q filed, results (8-K) |
| 29 May 2026 | 14.16% | 7.89 | |
| 15 Jun 2026 | 14.57% | 10.09 | |
| 30 Jun 2026 | 16.83% | 5.56 | |
| 15 Jul 2026 | 18.36% | 9.87 | |
| 31 Jul 2026 | 18.66% | 11.31 | |
| 14 Aug 2026 | 16.79% | 9.05 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 17.22% | 16.55 | |
| 15 Sep 2026 | 17.18% | 15.74 |
See also: Viridian Therapeutics, Inc.\DE's full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.